Position in MBAI
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,737
+$3,299 QoQ
Shares Held
770
+20.9% QoQ
Ownership
0.056%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1
of 14 holders
Holding Since
Dec 2022
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MBAI Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026CITADEL ADVISORS LLC holds $1,783,709,630 across 35 Diagnostics & Research names. MBAI ranks #33 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
574,992 | $288,277,988 | |
| 2 | CRL |
Charles River Laboratories International, Inc.
|
1,193,601 | $270,696,770 | |
| 3 | GH |
Guardant Health, Inc.
|
1,449,534 | $217,473,585 | |
| 4 | DHR |
Danaher Corp /De/
|
943,694 | $179,754,833 | |
| 5 | RVTY |
Revvity, Inc.
|
1,457,335 | $162,143,091 | |
| 6 | A |
Agilent Technologies, Inc.
|
1,101,501 | $146,312,377 | |
| 7 | TWST |
Twist Bioscience Corp
|
862,042 | $88,686,880 | |
| 8 | NTRA |
Natera, Inc.
|
265,607 | $72,099,020 |
All Filings in MBAI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,737 | 37,728 | Shares | Defined | 2026-08-14 | |
| 2025-06-30 | $3,438 | 31,218 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $2,359 | 20,854 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $3,187 | 22,536 | Shares | Defined | 2025-02-14 | |
| 2023-03-31 | $5,774 | 28,268 | Shares | Defined | 2023-05-15 | |
| 2022-12-31 | $9,472 | 30,139 | Shares | Defined | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||